Literature DB >> 22050419

Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia.

Vivek A Bhadri1, Toby N Trahair, Richard B Lock.   

Abstract

Glucocorticoids (GCs), such as prednisolone and dexamethasone, are key components in multi-agent chemotherapy protocols used for the treatment of acute lymphoblastic leukaemia (ALL). Approximately 10% of children with ALL will respond poorly to GCs, and GC resistance is associated with a significantly inferior outcome. This review summarises the current knowledge of GC resistance in ALL, including the roles of the GC receptor and its co-chaperone molecules, the pro-apoptotic and pro-survival B-cell lymphoma 2 family members and alternative non-apoptotic mechanisms of cell death. It concludes with a discussion on therapeutic attempts to overcome GC resistance.
© 2011 The Authors. Journal of Paediatrics and Child Health © 2011 Paediatrics and Child Health Division (Royal Australasian College of Physicians).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22050419     DOI: 10.1111/j.1440-1754.2011.02212.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  26 in total

Review 1.  [Association between BIM gene and glucocorticoid resistance in children with acute lymphoblastic leukemia].

Authors:  Jin-Yun Xu; Jian-Ming Luo
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-08

2.  Diagnostic value of the dual-luciferase report assay for predicting response to glucocorticoid in children with acute lymphoblastic leukemia.

Authors:  X Wang; P Chen; Y Sun; Y Chen; M Mao; T Jiang; J Ouyang
Journal:  Clin Transl Oncol       Date:  2017-04-25       Impact factor: 3.405

3.  REDD1/DDIT4-independent mTORC1 inhibition and apoptosis by glucocorticoids in thymocytes.

Authors:  Nicholas C Wolff; Renée M McKay; James Brugarolas
Journal:  Mol Cancer Res       Date:  2014-03-10       Impact factor: 5.852

4.  Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group.

Authors:  Terzah M Horton; James A Whitlock; Xiaomin Lu; Maureen M O'Brien; Michael J Borowitz; Meenakshi Devidas; Elizabeth A Raetz; Patrick A Brown; William L Carroll; Stephen P Hunger
Journal:  Br J Haematol       Date:  2019-04-07       Impact factor: 6.998

5.  Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.

Authors:  Connor P Hall; C Patrick Reynolds; Min H Kang
Journal:  Clin Cancer Res       Date:  2015-06-16       Impact factor: 12.531

Review 6.  Steroid resistance in leukemia.

Authors:  Darshan S Shah; Raj Kumar
Journal:  World J Exp Med       Date:  2013-05-20

7.  Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.

Authors:  Erich Piovan; Jiyang Yu; Valeria Tosello; Daniel Herranz; Alberto Ambesi-Impiombato; Ana Carolina Da Silva; Marta Sanchez-Martin; Arianne Perez-Garcia; Isaura Rigo; Mireia Castillo; Stefano Indraccolo; Justin R Cross; Elisa de Stanchina; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Giuseppe Basso; Jules P Meijerink; Carlos Cordon-Cardo; Andrea Califano; Adolfo A Ferrando
Journal:  Cancer Cell       Date:  2013-11-27       Impact factor: 31.743

8.  Bifunctional ligands allow deliberate extrinsic reprogramming of the glucocorticoid receptor.

Authors:  Jonas W Højfeldt; Osvaldo Cruz-Rodríguez; Yasuhiro Imaeda; Aaron R Van Dyke; James P Carolan; Anna K Mapp; Jorge A Iñiguez-Lluhí
Journal:  Mol Endocrinol       Date:  2014-01-01

9.  ESRRB regulates glucocorticoid gene expression in mice and patients with acute lymphoblastic leukemia.

Authors:  Kayleigh M Gallagher; Justine E Roderick; Shi Hao Tan; Tze King Tan; Leonard Murphy; Jun Yu; Rui Li; Kevin W O'Connor; Julie Zhu; Michael R Green; Takaomi Sanda; Michelle A Kelliher
Journal:  Blood Adv       Date:  2020-07-14

Review 10.  Role of Autophagy and Apoptosis in Acute Lymphoblastic Leukemia.

Authors:  Fang-Liang Huang; Sheng-Jie Yu; Chia-Ling Li
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.